Navigation Links
US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results
Date:2/28/2008

RECONCILIATION OF NET INCOME (LOSS) TO EBITDA AND ADJUSTED EBITDA

(in thousands)

(unaudited)

Three Months Three Months

Ended Ended Year Ended

December 31, September 30, December 31,

2007 2006 2007 2007 2006

Net income (loss) $(14,830) $3,253 $(4,194) $(34,973) $26,158

Add back:

Interest expense,

net 36,913 29,547 34,414 137,496 117,088

Income tax

(benefit)

provision (7,869) 3,654 (4,760) (17,447) 18,926

Depreciation and

amortization 23,456 21,660 23,239 89,331 83,334

Amortization of

stock compensation 277 746 15 753 2,149

Minority interest

expense 1,743 660 539 3,619 2,388

Other expense 11,573 - 312 11,885 -

EBITDA 51,263 59,520 49,565 190,664 250,043

Plus:

Loss on

extinguishment

of debt - - - 12,917 -

Impairment and

restructuring

charges 6,771 - 960 15,126 -

Adjusted EBITDA 58,034(1) 59,520(1) 50,525(1) 218,707(1) 250,043(1)

Changes in assets

and liabilities 45,954 29,394 (14,787) 77,708 (97,934)

Deferred income

tax provision

(benefit) (699) 1,414 (10,017) (11,689) 4,422

Interest

expense, net (36,913) (29,547) (34,414) (137,496) (117,088)

Income tax

benefit

(provision) 7,869 (3,654) 4,760 17,447
'/>"/>

SOURCE US Oncology Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26

Related biology technology :

1. Six UK Hospitals Join Together in Using Varian Medical Oncology Information Network
2. Genstruct CEO, Dr. Keith Elliston, Invited to Speak at Oncology Clinical Trial Summit
3. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
4. Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology
5. Pharsight Invited to Present on Oncology Modeling and Simulation at Quantitative Pharmacology Symposium in China
6. PRA International to Present Audioconference on Oncology Research - Nov. 8
7. IMPAC Medical Systems to Offer Revenue Cycle Inc.s Array of Oncology Products and Services to Customers
8. AG Mednet to Provide Image Network for Southwest Oncology Group
9. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
10. Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study
11. Oncology Metrics and Cureline Announce Joint Marketing Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)...  AnaptysBio, Inc., a leader in the ... announced the advancement of its first-in-class anti-interleukin-36 ... The Company,s anti-IL-36R therapeutic antibody, called ANB019, ... psoriasis (GPP), an orphan systemic inflammatory disease ... owned within AnaptysBio,s proprietary antibody pipeline and ...
(Date:4/16/2015)... 16, 2015  EMD Serono today announced the ... Germany , appointed Alise Reicin ... Global Clinical Development.  Dr. Reicin brings extensive research ... Oncology and Immunology. She is an accomplished pharmaceutical ... a Vice President in various capacities across R&D ...
(Date:4/16/2015)... 16, 2015 Fairleigh Dickinson University ... Gulfo to become the Executive Director of the ... announced the kick-off of the Initiative for Patient ... Dr. Gulfo, under the Rothman Institute of Innovation ... and in collaboration with FDU’s School of Pharmacy’s ...
(Date:4/16/2015)... Modality Solutions, a company that delivers ... industries, is pleased to announce its President, Gary ... Cold Chain IQ - Temperature Control Logistics and ... Global Cold Chain Connections, is dedicated to sharing ... pharmaceutical and healthcare supply chains. , Cold ...
Breaking Biology Technology:AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 2Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 3
... Allos,Therapeutics, Inc. (Nasdaq: ALTH ), a ... small molecule therapeutics for,the treatment of cancer, today ... JMP Securities Healthcare Focus Conference in Boston. ... p.m. (Eastern) on,Tuesday, November 13, 2007. There will ...
... ... treatment issues, SAN RAMON, Calif., Nov. 7 ... advisory group,designed to tackle head-on the increasingly complex ethical issues of,infertility medicine ... RSC,s ethics committee, believed to be the second of its kind among,infertility ...
... SyntheMed, Inc. (OTC,Bulletin Board: SYMD), a biomaterials ... tissue repair and drug delivery,products, announced today that ... the Securities and Exchange Commission (SEC) that, if,declared ... sell, from time to,time, up to $20 million ...
Cached Biology Technology:Allos Therapeutics to Present at the 2007 JMP Securities Healthcare Focus Conference 2California IVF Experts Tap Ethics Committee for Guidance 2SyntheMed Files Universal Shelf Registration 2
(Date:4/2/2015)... April 2, 2015 According to ... attributed to somewhat higher than 125 MSEK. This exceeds ... report 2014 that revenues for Q1 2015 would be ... reported for Q4 2014. The operating result for the ... The complete interim report will as previously communicated be ...
(Date:3/31/2015)... 2015  Elephant Talk Communications Corp. (NYSE MKT: ETAK) ... Software Defined Network Architecture (ET Software DNA® 2.0) platforms ... approximately $20.4 million for the year ended December 31, ... the year ended December 31, 2013. ... completed its multi-year transition away from its legacy landline ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has announced ... 2015-2019" report to their offering. The ... at a CAGR of 23.5 percent over the period ... and the growth prospects of the Global Iris Recognition ... size, the report considers the revenue generated from sales ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... CORVALLIS, Ore. A new study by Oregon State ... often know what kinds of foods they should be eating, ... money for meals. Joan Gross and Nancy Rosenberger, both ... rural Oregonians living in poverty by conducting in-depth interviews with ...
... it is for pregnant women to eat good, nutritious food. ... children who are less likely to develop type 1 diabetes, ... at the University of Gothenburg, Sweden. The ... conducting a population study called ABIS (All Babies in Southeast ...
... Ala. An experimental drug cocktail that includes ... hope in developing a single agent to treat ... in the University of Alabama Birmingham (UAB) Division ... the triple combination of oseltamivir (Tamiflu), amantadine (Symmetrel) ...
Cached Biology News:Poor in rural Oregon face 'double binds' when getting food 2Poor in rural Oregon face 'double binds' when getting food 3Vegetables can protect unborn child against diabetes 2Triple-combo drug shows promise against antiviral-resistant H1N1, UAB researcher says 2
... • Enzyme concentration - 5 units/µL ,• ... higher yields ,• Leaves an 'A' overhang ... polymerase which exhibits very high activity in ... To ensure the quality of the enzyme, ...
... Recombinant DNA polymerase from Thermus aquaticus expressed ... contamination; 1 tube of 250 units enzyme/tube ... (Low DNA), is the same enzyme as ... through a proprietary separation process to ensure ...
Our original highly-purified, robust Taq Polymerase which delivers consistently high yields and minimal background...
Taq DNA polymerase, 10,000U...
Biology Products: